FDA Grants Breakthrough Therapy Designation for Dizal Pharmaceutical’s DZD9008 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon20 Insertion
SHANGHAI, Jan. 27, 2022 /PRNewswire/ -- Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation to DZD9008 (Sunvozertinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon20 insertion mutations whose disease has progressed on...
Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources
DURHAM, N.C. and BEIJING, Jan. 27, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced the appointment of Karen D. Neuendorff as Chief People Officer and Head of Human...
Exyte Closes 2021 with Record Order Intake
- Order intake FY 2021 of over €8 billion, more than doubling YOY - Semiconductor and battery boom are main drivers for increased order intake- Outlook continues to be very positive STUTTGART, Germany, Jan. 27, 2022 /PRNewswire/ -- Exyte, a global leader in the design, engineering, and delivery of facilities for high-tech industries,...
Appendix 4C – Q2 FY22 Quarterly Cash Flow Report
Highlights: NZ's regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publications provide further evidence of potential of ATH434 to treat neurodegenerative diseases New US composition of matter patent secures exclusivity for a new class of compounds targeting Parkinson's and Alzheimer's...
Mentice’s CEO Goran Malmberg to present the company’s Year-end Report Q4 2021 at a webcast conference call on February 3rd at 9:30 CET
STOCKHOLM, Jan. 27, 2022 /PRNewswire/ -- Mentice AB (STO: MNTC) announces that the company will present its year-end report via a webcast conference call with the opportunity for interested parties to ask questions to CEO Goran Malmberg and CFO Gunilla Andersson. To register for the presentation of the Year-end Report Q4 for the period October – December 2021, which will be held...
ClinChoice Looks to Advance Global Safety Operations with LifeSphere MultiVigilance
MIAMI, Jan. 27, 2022 /PRNewswire/ -- ArisGlobal, the leading provider of life sciences software that automates core drug development with its end-to-end technology platform LifeSphere®, today announced ClinChoice has enlisted the LifeSphere MultiVigilance solution to manage pharmacovigilance activities worldwide. This partnership marks the leading global-based Clinical Research Organization (CRO) to entrust ArisGlobal's...
TriNetX Announces the Appointment of Shogo Wakabayashi as Japan Country Manager
CAMBRIDGE, Mass., Jan. 27, 2022 /PRNewswire/ -- TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, has announced that Shogo Wakabayashi has joined the company as Country Manager for Japan. Wakabayashi, a business leader with extensive global experience bringing new offerings to market, will...
I Peace’s Cell Manufacturing Facility “Peace Engine Kyoto” now registered as U.S. FDA Drug Establishment
PALO ALTO, Calif., Jan. 27, 2022 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up, announced that its cell manufacturing facility is now listed on the FDA "Drug Establishments Current Registration Site." The registration recognizes I Peace's cell manufacturing facility as suitable for drug manufacturing, based on detailed...
iMediSync Successfully Launches the Future of Tele-Medicare at CES 2022
SEOUL, South Korea, Jan. 26, 2022 /PRNewswire/ -- iMediSync, A biotech startup company from Seoul, South Korea, successfully debuted at CES 2022 to introduce the new trend of digital healthcare under their motto – Overcome Mental Pandemic in just 10 Min. Attendees waiting in the line to experience the iSyncWave at CES 2022 At the event,...
Lipidor Announces Enrolment of First Patients in a Phase III Study on AKP02 for Treatment of Psoriasis
STOCKHOLM, Jan. 26, 2022 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today reports that the first patients have been enrolled in a Phase III clinical study using AKP02 cutaneous spray (calcipotriol + betamethasone dipropionate 0.005 %/0.05 %) against mild to moderate psoriasis. Results from the study are expected to be presented in Q2 2022. The observer-blind...
